mCOMBRIAX Moderna Australia Pty Ltd
Product name
mCOMBRIAX
Sponsor
Accepted date
Mar-2026
Active ingredients
SARS-CoV-2 JN.1 mRNA, influenza virus haemagglutinin mRNA
Summary of proposed indication
mCOMBRIAX (a combined influenza and COVID‑19 mRNA vaccine) is proposed to be used to induce immunity and protection against influenza and COVID‑19.
It is for people aged 50 years and older.
This vaccine should be used according to official health recommendations.
It is for people aged 50 years and older.
This vaccine should be used according to official health recommendations.
Application type
A (new medicine)
Publication date
Mar-2026